Healthtech readiness review: users guide
Is your healthtech building a business that turns pilots into paying customers?
Clinical data, a clearly defined niche and a route from pilot to paid use are what make a healthtech investment case compelling. Steer helps founders identify what may strengthen, or weaken, that case before fundraising pressure limits their options.
Start with a free, ten-minute review.
- See your readiness score immediately.
- Receive a customised, human-led action plan within 24 hours.
- Identify the priorities that could strengthen your investment case and fundraising prospects.
- No payment. No obligation to engage Steer for further services.
The case
What makes a healthtech investment case compelling?
Investors do not judge a healthtech company by its software or its algorithm alone. They ask what the product does for a defined population, what evidence supports it, whether customers keep paying, and whether the company can grow without being slowed by legal or operational distractions.
-
1
A clearly defined niche, and protection that holds
Patents are useful mainly because they mark out your niche: the clinical problem, the population, the setting and the region you own. They also make it harder for a competitor to copy you exactly. Investors also watch for encumbrance, meaning an unresolved third-party claim. A claim like that pulls management's attention from growth into litigation and can cut the runway and value the company can build. Your data rights, trade secrets and know-how also protect your position, and each should be clear.
-
2
Evidence in the population you intend to serve
Does your product have clinical or performance data in its intended-use population? Have you compared it with a named alternative, and measured change in patient or clinician outcomes, not only accuracy? Investors look for evidence that holds up, not for a demonstration that works only in a controlled setting.
-
3
A pilot-to-paid pathway
How many pilot customers do you have, and how many pay? What share of pilots convert to paid use? Pilots show interest. Paying customers and a high conversion rate show a business. Investors expect a written plan with dated commercial milestones, such as contract counts or reimbursement decisions.
-
4
A regulatory, reimbursement and adoption route
Which regulatory route applies to your product, and has a pre-submission meeting been held where one is needed? Who uses the product, who buys it and who pays for it? A product that clinicians want but no payer covers is difficult to finance.
-
5
Data assets and value capture
A data pool or data lake becomes a durable asset only when the rights to it are clear, patient consent is documented and the data is de-identified. Investors also want a narrow initial segment with a named route to customers, a clear view of competitors, and a credible path to expansion. Cybersecurity and interoperability standards also matter, because hospitals and payers check them before buying.
-
6
Financing strategy and investment case
Does your plan explain why additional capital is needed, what it will achieve and how the resulting milestones could strengthen the company's value? The investment case should be written down and updated. A deck presents that case; it cannot replace it.
Leadership and exit
What else investors test.
Investors also look at whether the team covers clinical, regulatory, commercial, data and finance, and whether someone has taken a company through a financing or exit before. They ask whether the company can run without its founder for long periods, and whether the plan gives investors and the founder a realistic route to an exit.
What you receive
Your score, then your plan.
Your readiness score
Complete the review and see your score immediately. Use it as a structured starting point for understanding where your investment case may need further attention.
It is not a prediction of whether you will receive funding.
A customised action plan within 24 hours
Our team reviews your responses and prepares a human-led action plan identifying the priorities that could strengthen your investment case.
The plan is intended to help you understand:
- Which areas deserve attention first.
- Why those areas matter to investors.
- What evidence, analysis or strategic work may be needed.
- Which actions may require longer-term planning rather than an immediate fix.
The recommendations are based on your responses. The review does not replace a full clinical, regulatory, legal, data-protection or financial diligence exercise.
The review and initial action plan are free at present. There is no obligation to purchase advisory services.
Begin my free healthtech reviewTiming
When should you take the review?
Ideally, before you need to raise.
If you intend to close a financing round in 12 to 18 months, now may be the time to identify the pilot, evidence, data or commercial priorities that need to be addressed.
Waiting until you have only three to six months of runway can leave too little time to convert pilots, build evidence or settle a reimbursement route. Each of these can take substantial lead time.
You do not need to be preparing a Series A today. You need to be building a company that will be ready when the right financing opportunity arrives.
How it works
Four steps.
-
1
Complete the review
Answer 30 questions about your company's investment readiness. Each has four options, and the review takes about ten minutes.
-
2
See your score
Review your results immediately and identify the areas that may require attention.
-
3
Receive your action plan
Within 24 hours, our team reviews your responses and sends your customised action plan.
-
4
Decide what to do next
Use the plan independently or, if you wish, discuss potential next steps with us. There is no obligation to engage us.
Confidentiality
A note on confidentiality.
The review asks about the status of your company, not its detail. It does not need patient-level data, unpublished results, invention details or trade secrets, and you should not enter them.
Before submitting personal or company information, review our privacy policy to understand how it is collected, used and retained.
Frequently asked questions
Questions healthtech founders ask.
Is the review free?
Yes. The review and the initial human-led action plan are free at present.
Will I receive only a score?
No. Your score is available immediately, and our team will send a customised action plan within 24 hours.
Does a high score mean my company will raise successfully?
No. The review is a structured reading of your answers, not a funding prediction. Investment outcomes depend on many factors, including the quality of the opportunity, evidence, team, financing environment and investor requirements.
What if my score is low?
A lower score should be treated as an indication that certain areas may need attention, not as a verdict on the company's potential. The action plan is intended to help you identify priorities and determine what to do next.
Do I need a patent?
Not necessarily. Patents are most useful for marking out your niche and region and for making direct copying harder. Depending on the business, data rights, trade secrets and know-how may also protect your position. What matters is that your position is clear and free of unresolved third-party claims.
Do I need paying customers already?
Not necessarily. The review asks about pilots and paying customers, and your answers shape the plan. A company with pilots that are close to converting can still build a strong investment case.
What does Not applicable do?
It removes that question from your score. Use it when a question does not apply to your company. Use Not sure when you do not know the answer, because Not sure counts as partial credit and is not treated as No.
Will Steer expect me to purchase advisory services?
No. The initial review and action plan are free at present, with no obligation to purchase further services.
Begin
Build the investment case before you need the investment.
Start with a free, ten-minute healthtech review.
Begin my free healthtech review